Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Monitoring treatment and managing adherence in schizophrenia.

Marder SR.

J Clin Psychiatry. 2013 Oct;74(10):e21. doi: 10.4088/JCP.12117tx2c.

2.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
3.
4.

Treatment adherence in schizophrenia and schizoaffective disorder.

Goff DC, Hill M, Freudenreich O.

J Clin Psychiatry. 2011 Apr;72(4):e13. doi: 10.4088/JCP.9096tx6cc.

5.

A pilot study of barriers to medication adherence in schizophrenia.

Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G.

J Clin Psychiatry. 2004 Feb;65(2):211-6.

PMID:
15003075
6.

Improving treatment adherence in patients with schizophrenia.

Kane JM.

J Clin Psychiatry. 2011 Sep;72(9):e28. doi: 10.4088/JCP.9101tx2c.

7.

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.

Agid O, Foussias G, Remington G.

Expert Opin Pharmacother. 2010 Oct;11(14):2301-17. doi: 10.1517/14656566.2010.499125. Review.

PMID:
20586707
8.

[Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].

Azorin JM.

Encephale. 2013 Sep;39 Suppl 2:S121-3. doi: 10.1016/S0013-7006(13)70107-6. French.

PMID:
24084422
9.
10.

[Lifelong relapse prevention with antipsychotics in schizophrenia].

Hasan A, Wobrock T.

Psychiatr Prax. 2010 Sep;37(6):268-70. doi: 10.1055/s-0030-1248517. Epub 2010 Aug 27. German. No abstract available.

PMID:
20803409
11.

Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD.

J Clin Psychiatry. 2013 Dec;74(12):1249-55. doi: 10.4088/JCP.12m08331.

12.

Substance abuse and the management of medication nonadherence in schizophrenia.

Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M.

J Nerv Ment Dis. 2006 Jun;194(6):454-7.

PMID:
16772865
13.

Overview of partial compliance.

Marder SR.

J Clin Psychiatry. 2003;64 Suppl 16:3-9. Review.

15.

Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.

Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU.

J Clin Psychiatry. 2013 Oct;74(10):957-65. doi: 10.4088/JCP.13r08440.

PMID:
24229745
16.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
17.

Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.

Correll CU.

J Clin Psychiatry. 2014 Nov;75(11):e29. doi: 10.4088/JCP.13024tx3c. Review.

19.

Relapse prevention and recovery in the treatment of schizophrenia.

Schooler NR.

J Clin Psychiatry. 2006;67 Suppl 5:19-23.

20.

A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia.

Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E.

BMC Psychiatry. 2012 Mar 20;12:20. doi: 10.1186/1471-244X-12-20.

Supplemental Content

Support Center